INTRODUCTION {#s1}
============

Bosch--Boonstra--Schaaf optic atrophy syndrome (BBSOAS) is a recently described autosomal dominant disorder characterized by optic atrophy and/or hypoplasia, developmental delay, and intellectual disability ([@KAIWARMCS002162C6]; [@KAIWARMCS002162C2]; [@KAIWARMCS002162C5]; [@KAIWARMCS002162C7]). This disorder is caused by alterations in *NR2F1*, a highly conserved nuclear receptor protein that regulates transcription (MIM: 132890). *NR2F1* belongs to family of orphan nuclear receptors. It has two functional domains, the DNA-binding domain (DBD) and the ligand-binding domain (LBD), both of which are highly conserved across the members of the nuclear receptor family; the ligand for the LBD is, however, still unknown. It is very similar to its mouse counterpart, *COUP-TF1*, which has been extensively studied using knockout models. Many physiological roles of *COUP-TF1* have been delineated as a result---neurogenesis ([@KAIWARMCS002162C32]; [@KAIWARMCS002162C29]), eye development ([@KAIWARMCS002162C27]), cortical patterning ([@KAIWARMCS002162C9]), to name a few. Most variants in *NR2F1* described thus far have been missense variants that lead to haploinsufficiency or dominant negative effects and are predominantly located in the two functional domains. A smaller number of indels and larger deletions have also been reported ([@KAIWARMCS002162C6]; [@KAIWARMCS002162C2]; [@KAIWARMCS002162C7]). Here we describe two unrelated patients, with novel, de novo, missense variants in *NR2F1*, with new clinical features, not yet described for this syndrome. We also review the phenotypes of published cases and discuss their relation to the location of the variants. Using molecular modeling we are also able to demonstrate the putative effect of the two missenses on protein function, generating a hitherto undescribed molecular model for the LBD of *NR2F1* in the process.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

### Case 1 {#s2a1}

The patient was a third child born after normal pregnancy to a 32-yr-old mother. Apgar scores were 9 and 9 at 1 and 5 min, respectively, and birth weight was 6 pounds and 14 ounces (2785 g). The patient has had problems with feeding since birth and his psychomotor development was delayed. At age 1 yr the patient was functioning at a 2-month developmental level. One episode of infantile spasms was reported at 6 months that resolved with a single dose of ACTH; prophylaxis was not begun. He underwent bilateral inguinal herniorraphy at 10 months and subsequently received a gastrostomy tube to facilitate feeding. He was evaluated in the genetics clinic at 14 yr of age. His weight was 27.60 kg, height was 147 cm, and head circumference was 55 cm. Facial features were notable for mild dolichocephaly, mild midface hypoplasia, deep-set eyes with short palpebral fissures, large protruding ears with simplified helix and deficient lobuli, bilateral skin tags on the posterior aspect of the ear lobes, and micro- and retrognathia with large appearing teeth ([Fig. 1](#KAIWARMCS002162F1){ref-type="fig"}A). The patient was nonverbal with very limited social interaction and needed assistance with ambulation. Self-stimulating behavior was observed in the form of constant rocking back and forth and repetitive movements of his arms. Mild facial weakness, global hypotonia, diminished muscle mass, and motor apraxia were evident. Deep tendon reflexes were bilaterally brisk. The patient was able to localize touch and there was no cerebellar involvement. Short stature, both height and weight consistently below the third percentile, was recorded between 14 and 19 yr ([Fig. 1](#KAIWARMCS002162F1){ref-type="fig"}B,C). Bone age was ∼12.5 years at a chronological age of 15 yr, representing a delay of greater than 3 SDs. Brain magnetic resonance imaging (MRI) was unremarkable and limited ophthalmologic evaluation disclosed mild optic nerve hypoplasia bilaterally. An awake and asleep computer-assisted prolonged video EEG recorded left occipital onset seizure with secondary generalization, dysrhythmia grade 3, generalized and multifocal spikes and sharp waves, and right temporal intermittent rhythmic delta activity. Cerebrospinal fluid (CSF) examination was significant for a very low level of hydroxyindoleacetic acid (5-HIAA) of 19 nmol/l (normal range 67--140 nmol/l) and a low level of homovanillic acid (HVA) of 68 nmol/l (normal level of 145--326 nmol/l), whereas concentrations of 3-methyldopa, tetrahydrobiopterin, neopterin, and 5-methyltetrahydrofolate reductase were within the laboratory reference range. The overall phenotype was significant for optic nerve hypoplasia, severe intellectual disability with absent speech and limited ambulation, hypotonia, dysmorphic facies, short stature with delayed bone age, and low levels of 5-HIAA and HVA in CSF.

![Phenotype of Case 1 with Bosch--Boonstra--Schaaf optic atrophy syndrome. (*A*) Facial features: deep-set eyes, midface hypoplasia, simplified ear lobules, protruding ears, micrognathia, and retrognathia. (*B*) Height chart and (*C*) weight chart. Yellow crosses indicate serial measurements of the patient\'s height and weight. All marks fall consistently below the third percentile.](KaiwarMCS002162_F1){#KAIWARMCS002162F1}

### Case 2 {#s2a2}

The patient was the first child born at 35 weeks via C-section following premature rupture of membranes to a 25-yr-old mother. The pregnancy was complicated by hyperemesis gravidarum and maternal hypertension in the last trimester. Birth weight was 5 pounds and 15 ounces (2336 g). Feeding difficulties were noted at birth and a nasogastric tube was placed for the first 3 days, after which the infant was bottle-fed. At 5 1/2 weeks a heart murmur was noted and subsequent echocardiogram revealed a bicuspid aortic valve as well as a mildly dilated aortic root. These have remained stable in follow-up echocardiograms. Hypotonia was noted around 15 months. Anisometric amblyopia in the left eye was diagnosed at 17 months, and the patient underwent left lateral rectus recession for left dissociated horizontal deviation at 5 years. There was significant developmental delay, both motor and speech, with the patient functioning at a 6--8-month-old level at 15 months and at 2-year-old level at 5 years of age. The patient exhibited significant repetitive behavior such as rocking or banging her head against a wall, particularly while trying to fall asleep. On examination at age 2 years height was at 26th centile and weight was at 64th centile ([Fig. 2](#KAIWARMCS002162F2){ref-type="fig"}). The patient was mildly dysmorphic with slight hypertelorism, prominent synorphrys, simplified cupped ear helices, and large head (head circumference at 2 yr was 53 cm, 97th percentile). Wide proximal phalanges as well as mild hypotonia were also noted. The patient had normal hearing. MRI was not performed.

![Phenotype of Case 2 with Bosch--Boonstra--Schaaf optic atrophy syndrome. (*A*) Facial features: hypertelorism, prominent synorphrys, simplified cupped ear helices, and large head. (*B*) Height chart and (*C*) weight chart. Yellow crosses indicate serial measurements of the patient\'s height and weight.](KaiwarMCS002162_F2){#KAIWARMCS002162F2}

Genomic Analyses {#s2b}
----------------

### Case 1 {#s2b1}

Genetic testing for fragile X, Prader--Willi, and Angelman syndromes (including *UBE3* sequencing), *MECP2*, *TGF*β*R1*, and *TGF*β*R2* were normal. *PTEN* gene analysis revealed a variant in the 5′ UTR c.488_486dupGGC, inherited from the father. This variant was not interpreted as being phenotypically significant, given that the father was normal. Karyotype performed on skin fibroblasts was normal (46,XY). Chromosome microarray analysis revealed two copy-number changes. The first was a maternally inherited 58-kb duplication, 3p13(71,152,133--71,210,298) ×3, which included the 5′ UTR, exon1, and exon 2 of *FOXP1* gene (OMIM: 605515). Although deletions in this gene have been associated with intellectual disability, language impairment, and autism ([@KAIWARMCS002162C14]), this variant was classified as a familial variant with no phenotypic significance. The second, a paternally inherited 700-kb interstitial deletion at 7p14.3 (33,772,968--34,472,618) ×1, covers a region that includes two genes (*BMPER* and *NPSR1*). This deletion was reported as likely benign. Clinical whole-exome sequencing performed on the proband and his parents identified a novel, de novo, heterozygous, missense variant in the *NR2F1* gene (NM_005654.5), c.257G\>T, p.Cys86Phe ([Table 1](#KAIWARMCS002162TB1){ref-type="table"}). The C86 position of *NR2F1* is a highly conserved in orthologous protein sequences from human to *Drosophila*. No variants resulting in C86F in *NR2F1* are reported in any of the major population databases (ESP \[[@KAIWARMCS002162C8]\], ExAC \[[@KAIWARMCS002162C18]\], gnomAD \[[@KAIWARMCS002162C18]\], 1000 Genomes \[[@KAIWARMCS002162C11]\], dbSNP \[[@KAIWARMCS002162C26]\]). A synonymous change encoding this residue is reported in ExAC at a very low frequency (3 in 45,280). Bioinformatics algorithms were applied to predict the effect of C86F (SIFT score, 0 \[[@KAIWARMCS002162C17]\]; PolyPhen-2 score, 1.000 \[[@KAIWARMCS002162C1]\]), which agreed that the variant might be damaging to the protein.

###### 

Novel NR2F1 variants

  Gene      Transcript    Chromosome position (GRCh37/hg19)   HGVS                      Type/effect             Genotype       ClinVarID      dbSNP       Allele frequency ExAC/gNOMAD (all)   In silico tools (PolyPhen-2, SIFT)   Predicted effects with molecular modeling and dynamics simulations
  --------- ------------- ----------------------------------- ------------------------- ----------------------- -------------- -------------- ----------- ------------------------------------ ------------------------------------ --------------------------------------------------------------------
  *NR2F1*   NM_005654.5   5:92920986                          c.257G\>T, p.Cys86Phe     Substitution/missense   Heterozygous   SCV000599463   No record   No record                            Damaging                             Decreases stability of the zinc-binding domain
                          5:92929391                          c.1115T\>C, p.Leu372Pro   Substitution/missense   Heterozygous   SCV000599464   No record   No record                            Damaging                             Disrupts dimerization interface of the ligand-binding domain

### Case 2 {#s2b2}

Genetic testing for fragile X syndrome, Cornelia de Lange syndrome, and chromosomal microarray were normal. Clinical whole-exome sequencing performed on the proband and her parents found two paternally inherited missense variants, *NOTCH1* (NM_01617.4) c.7115G\<A, p.Arg2372Gln and *SGSH* (NM_000199.3) c.220C\>T, p.Arg74Cys. A cardiac ultrasound on the father could not be performed to help differentiate if the bicuspid aortic valve is a coincidental finding in the patient or if the *NOTCH1* variant is likely responsible for this cardiac finding. A novel de novo, heterozygous, missense variant in the *NR2F1* gene (NM_005654.5), c.1115T\>C, p.Leu372Pro was identified ([Table 1](#KAIWARMCS002162TB1){ref-type="table"}). The L372 residue of NR2F1 is conserved in orthologous protein sequences from human to *Caenorhabditis elegans*. No variants resulting in L372P in *NR2F1* are reported in any of the major population databases (ESP, ExAC, gnomAD, 1000 Genomes, dbSNP). Bioinformatics algorithms were applied to predict the effect of L372P (SIFT score, 0; PolyPhen-2 score, 1.000), which agreed that the variant might be damaging to the protein.

Molecular Modeling and Dynamics Simulations {#s2c}
-------------------------------------------

Molecular modeling was used to provide a more detailed model to inform our clinical interpretation of these novel variants.

### NR2F1 C86F Alters Zinc Ion Coordination and Decreases Stability of the Zinc-Binding Domain {#s2c1}

The Cys86Phe substitution lies in a highly conserved zinc-finger (ZF) nuclear hormone receptor-type domain, which is the first of two ZF domains within the DNA-binding domain. Each zinc-finger domain has four cysteine residues that coordinate the bound ion, and Cys86 is among them. Previous studies have established that changes in the DNA-binding domain disrupt transcriptional activity ([@KAIWARMCS002162C7]), and we hypothesized that changes to Cys86 may also have this effect. Thus, a homology-based protein model was developed and used in an in silico test for the effect of C86F on the structure and dynamics of the ZF domain ([Fig. 3](#KAIWARMCS002162F3){ref-type="fig"}A--C; see Methods for details). In our duplicate molecular dynamics (MD) simulations of the DNA-bound form, we identified differences in the time-dependent dynamics of the protein wherein the variant caused the structure to adopt a different conformation ([Fig. 3](#KAIWARMCS002162F3){ref-type="fig"}D). We quantified this relationship using principal component (PC) analysis. Further, the distances between residues that make up the zinc-binding site are more variable for C86F compared with wild type (wt) ([Fig. 3](#KAIWARMCS002162F3){ref-type="fig"}E,F). Changes in the geometry of the zinc coordination center for C86F simulations were evident ([Fig. 3](#KAIWARMCS002162F3){ref-type="fig"}C), indicating that the variant is likely to alter zinc ion coordination and thereby the stability of the domain. We performed MD of apo (no DNA bound) NR2F1 in triplicate and at two temperatures (300°K, room temperature, and 360°K) in order to better understand the potential effects of C86F on stability and folding. Using the same analyses as we used to quantify differences in the DNA-bound form, significant and consistent distortions to the zinc-binding site were observed, as measured by the separation of coordinating cysteine residues ([Fig. 3](#KAIWARMCS002162F3){ref-type="fig"}G). Altered dynamics were enhanced at higher temperature ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002162/-/DC1)). At a global level, C86F induced larger root-mean-square deviation (RMSD), a measure of the difference in the global shape of NR2F1, at both temperatures, as well as increased root-mean-square fluctuation (RMSF), a measure of each residue\'s mobility ([Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002162/-/DC1)). To understand the potential functional significance of the observed changes to NR2F1 in our simulations, we also simulated four previously established pathogenic variants: R112K, R142L, C128R, and F110del ([Fig. 4](#KAIWARMCS002162F4){ref-type="fig"}). We have summarized the impact of variants using a simple metric---the separation between the center of mass (COM) of the DNA and protein. This simple metric summarizes across three types of effects: alteration in specific DNA interactions by Arg residues (R112K and R142L), local loss of structure due to Zn^+2^ binding site alteration (C86F and C128R), and collapse of the structure due to loss of F110 in the hydrophobic core. Although the detailed changes in the structure of NR2F1 and its interactions with DNA differ by each variant, the impact on how the protein interacts with DNA is consistent across pathogenic variants and the VUS observed in our patient case.

![C86F leads to distortion of the zinc-binding site. The zinc-finger domain of NR2F1 and bound DNA are shown in cartoon representation. Solvent atoms are hidden for clarity, and zinc ions are represented by purple spheres. (*A*) Molecular model of NR2F1 zinc-finger (ZF) domains shows the structural role of C86. (*B*) A representative from among the largest deviations in wt simulations is shown. Although the zinc ion has moved, the geometry of the binding site is preserved. (*C*) Throughout simulations of F86, the geometry of the zinc-binding site is significantly altered and zinc ion interacts with residues outside of the binding site. (*D*) Plotting each frame from the simulation as a point in the dominant principal component (PC) subspace, the two proteins adopted different conformations. (*E*,*F*) The distance (Å) between the C^α^ atom of residue 86 and of two of the other zinc-coordinating residues. Both measures showed stability for the duplicate wt simulations, but instability for C86F. (*G*) The distance (Å) between zinc-coordinating residues across apo simulations. Probability density plots and structural representatives (*inset*) show that across triplicate simulations of apo-NR2F1 at 300 K and 360 K, C86F led to greater instability around the ion-binding site.](KaiwarMCS002162_F3){#KAIWARMCS002162F3}

![Pathogenic variants in the DBD lead to greater separation from DNA. Four previously reported pathogenic variants were simulated similarly to C86F and wt. We measured the distance between the center of mass (COM) of NR2F1 and of the bound DNA fragment. The separation between the COM of each molecule was monitored, and all pathogenic variants lead to a significant increase. However, the two variants that directly altered zinc-binding residues, C128R and C86F, exhibited the greatest effect.](KaiwarMCS002162_F4){#KAIWARMCS002162F4}

### NR2F1 L372P Disrupts the Dimerization Interface of the Ligand-Binding Domain {#s2c2}

The Leu372Pro substitution lies in a ligand-binding domain (LBD) that is highly conserved (97% identical) compared with the paralog NR2F2, but for which the structure has not been experimentally determined. LBD of NR2F2 is also the dimerization domain. NR2F1 is known to bind DNA as dimers ([@KAIWARMCS002162C25]; [@KAIWARMCS002162C30]), and therefore it is very likely that the NR2F1 LBD is also the dimerization domain. We generated a molecular model of the NR2F1 LBD dimer from the experimental structure of an NR2F2 homodimer. In this model, the majority of the dimer interface is composed of hydrophobic residues within an α-helical secondary structure that we will refer to as the binding helix. L372P lies in the middle of the binding helix. Proline placed in the middle of an α-helix in soluble proteins is well known to destabilize the helix ([@KAIWARMCS002162C19]). Consequently, we hypothesize that the observed substitution will destabilize the ligand-binding helix. To test this hypothesis, we employed MD simulation and measured the conformational stability of the binding helix. Compared with wt and across triplicate simulations, heterodimers and homodimers of L372P exhibited lower α-helix content and greater conformational variability, as measured by RMSD ([Fig. 5](#KAIWARMCS002162F5){ref-type="fig"}). Therefore, MD simulations support our hypothesis that the binding helix is destabilized by L372P. Because it is known that NR2F1 binds DNA as a dimer, we hypothesize that loss of dimerization due to Leu372Pro would impair DNA binding and thereby alter transcriptional regulation.

![L372P destabilizes the ligand-binding domain (LBD) dimer interface. (*A*) Examination of our model of the LBD dimer revealed that L372 is in the center of the α-helix that makes up much of the dimer interface. (*B*) The dimerization helices from each monomer are arranged in parallel, leading to the L372P and G368D residues from each to be facing one another. (*C*) We observed loss of α-helical content within the dimerization helices after MD simulation. (*D*) L372P also leads to alteration of binding helix conformation as quantified by larger RMSDs.](KaiwarMCS002162_F5){#KAIWARMCS002162F5}

Our structural model also provided a mechanistic hypothesis for the effect of another observed NR2F1 LBD variant identified in association with BBSOAS and located within the binding helix---Gly368Asp ([@KAIWARMCS002162C7]). The binding helices from each monomer are aligned in parallel. In the dimerized form, each Glycine at position 368 faces one another. Substitution to a negatively charged Asp will affect dimerization by adding a larger side chain and a negatively charged surface. These two features are likely to destabilize NR2F1 dimerization.

DISCUSSION {#s3}
==========

NR2F1 (nuclear receptor group 2, family 1), also known as COUP-TF1 in mice, belongs to the group of orphan nuclear receptors. NR2F1 has been shown to be one of the transcription factors expressed in bones of the skull and limbs where it interacts with bone morphogenetic protein-4 (BMP-4) ([@KAIWARMCS002162C10]) and can be responsible for aberrant mineralization levels at these sites, define susceptibility to pathological osteopenic changes, and cause fate specification. Alterations in these activities can be hypothesized to lead to the delayed bone development that we report for the first time as being associated with this syndrome, as evidenced by short stature and delay in bone maturation in Case 1. NR2F1 influences the balance of cortical patterning between motor and sensory areas in the brain, a phenomenon known as arealization ([@KAIWARMCS002162C3]). Expression of NR2F1 in iPS cells has recently been shown to lead to their differentiation into cells that have the same neurotransmitter profiles as GABAergic neurons ([@KAIWARMCS002162C28]). The neurotransmitter abnormalities observed in Case 1 can be hypothesized to be the result of disturbances in arealization as well as differentiation of neuronal cells. Further characterization of NR2F1 and its role in the neuronal circuitry is needed to gain more insight into these mechanisms. Functional studies have confirmed a dominant negative effect ([@KAIWARMCS002162C7]) for previously reported pathogenic missense variants in the DNA-binding domain (DBD) of *NR2F1*. Case 2 exhibits a slightly minor phenotype of the disease, as do previously reported LBD variants. The previously reported cases ([@KAIWARMCS002162C7]) had only mild ophthalmologic findings, as does our case. No hypotonia was noted in the previous cases, whereas in our case hypotonia was noted in infancy but has resolved with growth. An MRI was not performed in our patient; however, the previously reported cases have normal MRIs. Including the two patients in this report, a total of 30 patients with BBSOAS have been described in the literature ([Table 2](#KAIWARMCS002162TB2){ref-type="table"}). Of these, there are eight patients with whole-gene deletions of *NR2F1* in Chr 5 encompassing *NR2F1* among other genes, ranging in size from 582 kb to 5 Mb. Smaller indels were reported in 5 of 30 cases. Missense mutations are the most common mechanism of variation, with 17 of 30 patients having de novo mutations. Of the missense mutations, 10 of 17 lie in the DNA-binding domain, four are in the start codon, and only three are in the ligand-binding domain, making a case for the DNA-binding domain being a mutational hotspot. Although phenotypic characteristics range from mild to severe for patients with all variants, patients with variants in the ligand-binding domains seem to have a milder degree of developmental delay, no hypotonia, no speech defects, no seizures, or no repetitive behaviors. These milder features do corroborate a possible genotype--phenotype relationship for this syndrome, with variants in the ligand-binding domain leading to a milder phenotype ([Table 2](#KAIWARMCS002162TB2){ref-type="table"}).

###### 

Variants in *NR2F1* and phenotypic features of patients with Bosch--Boonstra--Schaaf optic atrophy syndrome

  GRCh37(Chr 5) Sl. no.   NR2F1 Chr. position                                                NM_005654.5 cDNA nomenclature   AA change       Domain                                                                                 Inheritance   Gender   Age          Development   CVI                       Hypotonia              Oromotor dys
  ----------------------- ------------------------------------------------------------------ ------------------------------- --------------- -------------------------------------------------------------------------------------- ------------- -------- ------------ ------------- ------------------------- ---------------------- --------------
  1                       Chr 5: g.92920731                                                  c.2T\>G                         p?              Affects start codon, the third codon is also ATG, so alternate start possible          De novo       Male     7 yr         \+            Optic nerve hypoplasia    \+                     \+
  2                       Chr 5: g.92920731                                                  c.2T\>G                         p?              Affects start codon, the third codon is also ATG, so alternate start possible          De novo       Female   4 yr         \+            ONA                       −                      \+
  3                       Chr 5: g.92920731                                                  c.2T\>C                         p?              Affects start codon, the third codon is also ATG, so alternate start possible          De novo       Female   3 yr         \+            CVI                       \+                     −
  4                       Chr 5: g.92920732                                                  c.2T\>C                         p?              Affects start codon, the third codon is also ATG, so alternate start possible          De novo       Female   12 yr        \+            ONA                       \+                     \+
  5                       Chr.5: g.92920731\_ 92920733del                                    c.2_4delTGGinsG                 p?                                                                                                     De novo       Male     43 yr        \+            ONA                       \+                     \+
  6                       Chr.5: g.92920832\_ 92920842delinsCGCC                             c.103_113delinsC                Gly35Argfs\*8   DNA-binding domain                                                                     De novo       Male     30 yr        \+            ONA                       \+                     \+
  7                       Chr 5:g.92920986                                                   c.257G\>T                       Cys86Phe        DNA-binding domain, zinc ion bind                                                      De novo       Male     14 yr        \+            mild b/l                  \+                     \+
  8                       Chr 5: g.92921020del                                               c.291delC                       Tyr98Thrfs\*2   DNA-binding domain                                                                     De novo       Male     21 yr        \+            ONA                       \+                     \+
  9                       Chr.5: g.92921057\_ 92921059del                                    c.328_330delTTC                 Phe110del       DNA-binding domain                                                                     De novo       Female   6 yr         \+            ONA                       \+                     −
  10                      Chr.5: g.92921057\_ 92921059del                                    c.328_330delTTC                 Phe110del       DNA-binding domain                                                                     De novo       Male     7 yr         \+            −                         \+                     −
  11                      Chr 5: g.92921064                                                  c.335G\>A                       Arg112Lys       DNA-binding domain, putative DNA-binding site                                          De novo       Female   35 yr        IQ52          −                         NA                     NA
  12                      Chr 5: g.92921068                                                  c.339C\>A                       Ser113Arg       DNA-binding domain                                                                     De novo       Female   2 yr 4 mo    Delayed       CVI                       NA                     NA
  13                      Chr 5: g.92921073                                                  c.344G\>C                       Arg115Pro       DNA-binding domain                                                                     De novo       Male     12 yr        IQ48          CVI                       NA                     NA
  14                      Chr.5: g.92921111                                                  c.382T\>C                       Cys128Arg       DNA-binding domain                                                                     De novo       Male     6 yr         \+            ONA                       \+                     \+
  15                      Chr.5: g.92921132                                                  c.403C\>A                       Arg135Ser       DNA-binding domain, putative DNA-binding site                                          De novo       Female   4 yr         \+            CVI                       \+                     \+
  16                      Chr.5: g.92921142                                                  C.413G\>A                       Cys138Tyr       DNA-binding domain                                                                     De novo       Male     15 yr        \+            ONA                       −                      −
  17                      Chr.5: g.92921154                                                  c.425G\>T                       Arg142Leu       DNA-binding domain, putative DNA-binding site                                          De novo       Female   4 yr         \+            ONA                       \+                     \+
  18                      Chr.5: g.92921165                                                  c.436T\>C                       Cys146Arg       DNA-binding domain                                                                     De novo       Male     11 yr        \+            ONA                       \+                     \+
  19                      Chr.5: g.92921192                                                  c.463G\>A                       Arg155Thr       DNA-binding domain                                                                     De novo       Male     10 yr        −             −                         \+                     −
  20                      Chr 5: g.92923914                                                  c.755T\>C                       Leu252Pro       Ligand-binding domain, putative c                                                      De novo       Female   18 yr        IQ 55--65     CVI                       NA                     NA
  21                      Chr.5: g.92929379                                                  c.1103G\>A                      Gly368Asp       Ligand-binding domain                                                                  De novo       Male     21 yr        \+            −                         −                      −
  22                      Chr 5:g.92929391                                                   c.1115T\>C                      Leu372Pro       Ligand-binding domain                                                                  De novo       Female   15 mo        \+            −                         +, resolved with age   \+
  23                      Chr.5: 92,742,875-93,324,530 (hg18; NCBI Build 36.1, March 2006)   582 kb                                          Genes included: *FLJ42709, NR2F1, FAM172A, POU5F2*, and one microRNA gene, *MIR2277*   De novo       Male     8 yr, 3 mo   \+            ONA, small optic chiasm   \+                     \+
  24                      Chr 5: 92,856,299--93,054,63                                       0.2 Mb                                          Genes included: *NR2F1, FAM172A* (partial)                                             De novo       Female   8 yr         \+            ONA                       \+                     −
  25                      Chr 5: 92845157--93679748                                          0.83 Mb                                         Genes included: *NR2F1, FAM172A, KIAA0825* (partial)                                   Paternal      Female   24 yr        IQ 61--74     CVI                                              
  26                      Chr 5: 92,910,393--93,806,93                                       0.9 Mb\* 1st pt                                 Genes included: *NR2F1, FAM172A, KIAA0825* (partial)                                   NA            Male     35 yr        \+            ONA                       −                      −
  27                      Chr 5: 92,910,393--93,806,93                                       0.9 Mb\* 2nd pt                                 Genes included: *NR2F1, FAM172A, KIAA0825*(partial)                                    Paternal      Male     2 yr         \+            ONA                       \+                     \+
  28                      Chr 5: 92,878,375--94,046,21                                       1.2 Mb                                          Genes included: *NR2F1, FAM172A, KIAA0825, ANKRD31*                                    NA            Male     37 yr        IQ 70--96     ONA                       −                      −
  29                      Chr 5: 91,064,110--93,896,378                                      2.85 Mb                                         Genes included: *NR2F1, FAM172A, KIAA0825, ANKRD31*                                    De novo       Female   4 yr         Delayed       CVI                       NA                     NA
  30                      Chr 5: 90,566,268--95,580,99                                       5.0 Mb                                          Genes included: *NR2F1, FAM172A, KIAA0825, ANKRD32, MCTP30*                            NA            Female   6 yr         \+            −                         \+                     \+

  GRCh37(Chr 5) Sl. no.   Repetitive behavior   ASD   CSF             Seizures   Febrile seizure   Hearing loss               Spasticity   Speech                    Ophthalmologic exam                                                                                                      Bone age   Heart defect                                    Short stature   Height                    Weight                            Head circum               Reference
  ----------------------- --------------------- ----- --------------- ---------- ----------------- -------------------------- ------------ ------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------- ----------------------------------------------- --------------- ------------------------- --------------------------------- ------------------------- ----------------------------
  1                       \+                    \+    NA              −          −                 \+                         \+           Nonverbal                 Small optic nerves b/l                                                                                                   NA         NA                                              −               NA                        NA                                NA                        PMID 26986877
  2                       −                     −     NA              −          −                 −                          −            Expressive speech         Small and pale optic discs                                                                                               NA                                                         −               At birth, 34th centile    At birth, 4th centile             NA                        PMID 26986877
  3                       −                     −     NA              −          −                 −                          −            Nonverbal                 Intermittent accommodative left esotropia associated with hyperopia                                                      NA         NA                                              −               At birth, 97th centile    At birth, 62nd centile            NA                        PMID 26986877
  4                       OCD, ADHD, +          −     NA              \+         −                 \+                         −            Nonverbal                 NA                                                                                                                       NA         Atrial septal defect, spontaneously resolved    −               At birth, 34th centile    At birth, 18th centile            NA                        PMID 26986877
  5                       −                     −     NA              \+         −                 −                          −            Nonverbal                 Pale optic nerves                                                                                                        NA         NA                                              −               NA                        At birth, 39th centile            NA                        PMID 26986877
  6                       PDD-NOS, ADHD, +      \+    NA              \+         −                 \+                         −            NA                        Partial pale optic discs                                                                                                 NA         NA                                              −               At 27 yr, 84th centile    At birth, 95th centile            At 27 yr, 70th centile    PMID 26986877
  7                       \+                    −     Low 5-HIAA, L   \+         −                 −                          −            Non verbal                Mild b/l optic nerve hypoplasia                                                                                          Delayed    None                                            \+              At 14 yr, \<3rd centile   At 14 yr, less than 3rd centile   At 14 yr, 55cm            This report
  8                       OCD, ADHD, +          \+    NA              −          −                 Selective hearing          −            Delayed, limi             Optic nerve hypoplasia, surgically corrected strabismus                                                                  NA         NA                                              −               At birth, 62nd centile    At birth, 9th centile             NA                        PMID 26986877
  9                       −                     −     NA              \+         −                 −                          −            Nonverbal                 Optic nerve hypoplasia                                                                                                   NA         NA                                              −               At 4 yr, 75th centile     At 4 yr, \<5th centile            At 4 yr, 10th centile     PMID 26986877
  10                      −                     \+    NA              −          −                 −                          −            Nonverbal                 Normal                                                                                                                   NA         NA                                              −               NA                        NA                                NA                        PMID 26138355
  11                      OCD                   \+    NA              \+         NA                NA                         NA           NA                        Pale optic discs, b/l keratoconus, strabismus                                                                            NA         NA                                              \-              NA                        NA                                13th centile              PMID 24462372
  12                      NA                    NA    NA              NA         NA                NA                         NA           NA                        Pale optic disc, strabismus                                                                                              NA         NA                                              −               NA                        NA                                55th centile              PMID 24462372 and 26350515
  13                      NA                    NA    NA              NA         NA                NA                         NA           NA                        Small and large excavation of the optic disc, strabismus, latent nystagmus                                               NA         NA                                              −               NA                        NA                                98th centile              PMID 24462372 and 26350515
  14                      \+                    \+    NA              \+         −                 \+                         −            Nonverbal                 b/l small optic nerves                                                                                                   NA         NA                                              −               NA                        NA                                NA                        PMID 26986877
  15                      −                     −     NA              \+         −                 −                          −            NA                        Flat optic nerves, Lt. esotropia and amblyopia                                                                           NA         NA                                              −               NA                        NA                                NA                        PMID 26986877
  16                      \+                    \+    NA              −          \+                −                          −            NA                        b/l optic atrophy                                                                                                        NA         NA                                              −               At 14 yr, \<5th centile   At 14 yr, \<5th centile           At 14 yr, 43rd centile    PMID 26986877
  17                      −                     −     NA              \+         −                 −                          −            NA                        Alternating and variable intermittent esotropia and intermittent exotropia intermittent nystagmus, 2+b/l optic atrophy   NA         NA                                              −               NA                        At birth, 20th centile            NA                        PMID 26986877
  18                      \+                    −     NA              −          −                 −                          −            Nonverbal                 NA                                                                                                                       NA         NA                                              −               NA                        At birth, 96th centile            NA                        PMID 26986877
  19                      −                     −     NA              −          −                 −                          −            Delayed with dysarthria   Rt. Esotropia and amblyopia                                                                                              NA         NA                                              −               NA                        At birth, 66th centile            NA                        PMID 26986877
  20                      NA                    NA    NA                                                                                   NA                        Pale and large excavation of optic discs, strabismus, latent nystagmus                                                   NA         NA                                              −               NA                        NA                                55^th^ centile            PMID 24462372
  21                      \+                    \+    NA              \+         −                 −                          −            NA                        astigmatism, corrected                                                                                                   NA         NA                                              −                                                                                                     PMID 26986877
  22                      \+                    −     NA              −          −                 −                          −            Delayed                   Lt. anisometric amblyopia,                                                                                               Not done   Bicuspid aortic valve and dilated aortic root   −               At 2 yr, 26th centile     At 2 yr, 64th centile             At 2 yr, 97th centile     This report
  23                      NA                    NA    NA              −          −                 \+ b/l, mild, conductive   −            NA                        NA                                                                                                                       NA         NA                                              −                                                                           80th centile              PMID 23300014
  24                      ADHD, −               −     NA              −          −                 −                          −            NA                        Pale optic discs, strabismus                                                                                             NA         NA                                              −               At 6.5 yr, 10th centile   At 6.5 yrs, 18th centile          At 6.5 yr, 50th centile   PMID 26986877
  25                      NA                          NA                                                                                   NA                        Partial pale optic discs, latent nystagmus, deep anterior chamber, mild lens opacity                                     NA         NA                                              −                                                                           99thcentile               PMID 24462372
  26                      ADHD, −               −     NA              −          −                 −                          −            NA                        Pale optic discs, exotropia                                                                                              NA         NA                                              −               At 34 yr, 40th centile    NA                                At 34 yr, 86th centile    PMID 26986877
  27                      −                     --    NA              −          −                 −                          −            Delayed                   NA                                                                                                                       NA         NA                                              −               At 11 mo, 93rd centile    At 11 mo, 8th centile             At 11 mo, 30th centile    PMID 26986877
  28                      −, PDD- NOS           \+    NA              −          −                 −                          −            NA                        b/l amblyopia, surgically co                                                                                             NA         NA                                              −               NA                        NA                                NA                        PMID 26986877
  29                      NA                    NA    NA              NA         NA                NA                         NA           NA                        Small and pale optic discs,                                                                                              NA         NA                                              −                                                                           50^th^ centile            PMID 24462372
  30                      −                     −     NA              −          −                 −                          −            −                         Myopia                                                                                                                   NA         NA                                              −               At birth, 51st centile    At birth, 55th centile            \+ 3.23SD                 PMID 26986877

AA, amino acid; ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; b/l, bilateral; CSF, cerebrospinal fluid; CVI, cortical visual impairment; mo, months; MRI, magnetic resonance imaging; NA, not available; OCD, obsessive-compulsive disorder; ONA, optic nerve atrophy; PDD-NOS, pervasive development disorder not otherwise specified; SI. no., serial number; yr, years.

Molecular modeling predicted the effects of these variants on protein function and exemplified the practical application of these methods as recently advocated ([@KAIWARMCS002162C23]). The application of molecular modeling and computational methods was used to characterize the two reported novel variants in NR2F1, the first in the DBD and the second in its LBD. Alterations to zinc-binding residues, including our novel C86F, were associated with the more significant alterations in our simulations, compared to other pathogenic variants. This may be due to two effects: First, the local unfolding of the zinc-binding site is a more drastic structural change, compared to alteration of a surface property, as in the substitution of arginine residues. Second, we have not considered the difference in contact between motif-containing DNA and nonspecific DNA. Therefore, clearer differences from wt for previously identified pathogenic variants may be achieved by considering a more specific metric, but the effect of C86F on NR2F1 structure is clear.

This report reiterates a possible genotype--phenotype correlation, with variants in the ligand-binding domain leading to milder phenotypes. It also potentially expands the phenotypic spectrum of BBSOAS to include short stature with delayed bone age and low levels of serotonin and dopamine metabolites (5-HIAA; HVA) and macrocephaly. We cautiously interpret these new features as phenotypic expansions of this newly described and currently evolving syndrome. The complete description of the phenotype will be better established as more cases of this rare disease are reported. Interestingly, although one of our patients had amblyopia, we did not see optic atrophy in either of our patients. Only 15 of the 28 previously reported cases have documented optic nerve atrophy (ONA; [Table 2](#KAIWARMCS002162TB2){ref-type="table"}), whereas seven of the remaining 13 had a diagnosis of cerebral visual impairment (CVI; [Table 2](#KAIWARMCS002162TB2){ref-type="table"}). Detailed ophthalmologic exams were available in 27 of 30 cases. Small or pale optic discs, strabismus, and esotropia and amblyopia were commonly encountered ([Table 2](#KAIWARMCS002162TB2){ref-type="table"}). These findings suggest that that optic atrophy is an inconsistent feature. Renaming the syndrome as BBSS may be more reflective of this phenotypically evolving recently discovered syndrome associated with *NR2F1* mutations.

METHODS {#s4}
=======

Sample Collection and Whole-Exome Sequencing {#s4a}
--------------------------------------------

Whole-exome sequencing (WES) was performed on genomic DNA extracted from all samples submitted. The exome was captured utilizing a custom reagent developed by the Mayo Clinic and Agilent Technologies, targeting 19,456 genes and 187,715 exons using 637,923 probes to capture a 54.1-Mbp total region. Sequencing was performed on an Illumina HiSeq 2500 Next-Generation sequencing instrument, using HapMap Sample NA12878 as an internal control. Paired-end 101-bp reads were aligned to a modified human reference genome (GRCh37/hg19) using Novoalign (Novocraft Technologies). Sequencing quality was evaluated using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). All germline variants were jointly called through GATK Haplotype Caller and GenotypeGVCF ([@KAIWARMCS002162C21]). Each variant was annotated using the BioR Toolkit ([@KAIWARMCS002162C16]) and subsequently evaluated for clinical relevance. Sequence coverage is detailed in [Table 3](#KAIWARMCS002162TB3){ref-type="table"}.

###### 

Sequencing coverage

            Total mapped reads (millions)   Reads on target (%)   Duplication reads (%)   Target reads \>20% (%)   c.257G\>T (reads---total:variant)
  --------- ------------------------------- --------------------- ----------------------- ------------------------ -----------------------------------
  Case 1                                                                                                           
  Proband   115.7                           73.0                  8.2                     \>97                     197:97
  Mother    130.6                           72.0                  9.4                     \>97                     205:0
  Father    90.1                            73.0                  7.4                     \>97                     148:0
  Case 2                                                                                                           
  Proband   135.6                           87.4                  9.3                     \>97                     237:107
  Mother    161.0                           87.3                  7.6                     \>97                     319:0
  Father    150                             86.6                  11.9                    \>97                     262:0

Molecular Modeling and Molecular Dynamic Simulations {#s4b}
----------------------------------------------------

We generated a molecular model of the DNA-bound zinc-finger domain of NR2F1 using the homologous (54% identical) crystal structure of RXRA (1BY4 \[[@KAIWARMCS002162C31]\]) and validated it against the experimentally solved solution structure (DOI: 10.2210/pdb2ebl/pdb.). Explicit solvent molecular dynamics (MD) simulations were carried out using NAMD ([@KAIWARMCS002162C24]) and the CHARMM27 with CMAP ([@KAIWARMCS002162C20]) force field. The wt system was solvated ([@KAIWARMCS002162C13]), ions added to 150 mM NaCl, and computational mutagenesis used to make the C86F model. The wt and C86F proteins were minimized, heated, and equilibrated over a combined 5 nsec each, and in duplicate (NPT). A further 25 nsec of simulation trajectory was generated for each (NVT) and the final 20 nsec analyzed. Additional and independent duplicate 2 nsec explicit solvent MD simulations were generated using the CHARMM force field within Discovery Studio ([@KAIWARMCS002162C4]). Simulations of wt and C86F were also performed without DNA present (apo) and at two temperatures: 300°K and 360°K. Triplicate simulations of each condition were performed in NAMD with systems prepared similarly to above. For each, 22 nsec of simulation was generated and the final 15 nsec analyzed. Thus, a total of 384 nsec (264 nsec apo, 120 nsec holo) of MD simulation was leveraged to characterize the effects of C86F.

We additionally studied four previously reported pathogenic variants: R112K, R142L, F110del, and C128R. Triplicate explicit solvent MD simulations of these four variants, wt, and C86F were generated by a similar procedure to the above but with the following modifications: First, the bound DNA fragment was restrained in simulation to limit its dynamics. Second, the protein was initially constrained using harmonic restraints and these restraints were slowly released over 5 nsec. Finally, 20 nsec of production simulation was generated and analyzed.

Analysis was carried out using custom scripts, leveraging VMD ([@KAIWARMCS002162C15]) and the Bio3D R package ([@KAIWARMCS002162C12]). Protein structure visualization was performed in PyMol ("The PyMOL Molecular Graphics System. Version 1.5.0.3") and VMD. Prior to analysis, all trajectories were aligned to the initial wt conformation using C^α^ atoms. PC analysis was performed using C^α^ atoms in Cartesian space.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The variants mentioned in this report were deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) on 9/12/2017. The ClinVar IDs are SCV000599463 and SCV000599464 for the NM_005654.5:c.257G\>T and NM_005654.5:c.1115T\>C variants, respectively.
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